Glucotrack CEO to Showcase Implantable Glucose Monitor at LSI USA Summit
Event summary
- Glucotrack CEO Paul V. Goode to present at LSI USA ’26 Summit on March 17, 2026.
- Presentation will cover first-in-human study results and regulatory strategy for U.S. clinical trial.
- Company’s CBGM technology aims for three-year sensor longevity with no on-body wearable component.
- Glucotrack targets substantial unmet needs in diabetes management with implantable device.
The big picture
Glucotrack’s focus on long-term implantable glucose monitoring aligns with broader trends in diabetes management toward less invasive, more user-friendly solutions. The company’s strategic push for regulatory approval and commercialization comes as the medtech sector increasingly prioritizes patient-centric device design. Success hinges on navigating clinical trial hurdles and securing partnerships to scale manufacturing and distribution.
What we're watching
- Regulatory Strategy
- How Glucotrack’s approach to U.S. clinical trials will impact approval timelines and market entry.
- Commercialization Pace
- Whether the company can sustain momentum toward a fully implantable device amid competitive pressures.
- Investor Engagement
- The level of interest from partners and investors following the summit presentation.